Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.
How this was made
The 30-second read
Why it matters
The trial met primary and secondary endpoints, showing a statistically significant reduction in disease severity, which could revive Amgen's lupus franchise.
Market read
Positive data may prompt short‑term buying pressure on AMGN and influence peer biotech valuations.
What to watch
Small sample size (72 patients) and lack of long‑term safety data could temper enthusiasm.
Background
Amgen acquired the antibody from Horizon Therapeutics in 2023 and is now reporting phase 2 data for discoid lupus.
Ticker impact
Amgen disclosed phase 2 data showing its antibody daxdilimab cut lupus severity by 6 points versus placebo.
likely upside as market prices in the favorable trial outcome
The data are new, material to Amgen's pipeline and represent the first positive readout for this asset.
Market effects
May boost sentiment for biotech firms with lupus or autoimmune pipelines.
Limited to US biotech sector; no broader regional effect.
Modest, confined to investors tracking clinical trial outcomes.
Counterpoint
Skeptics may note the earlier failure in systemic lupus and question durability of the signal.
Key entities
- companyAmgen
US biotech firm reporting the trial results.
- companyHorizon Therapeutics
Original developer of daxdilimab, acquired by Amgen.
